SLS
Live chart
What they do
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
For information only · Important disclosures
Grades vs sector
No sector grades for SLS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2023-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.57 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.10 vs trailing $-0.21. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 186.9 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2023 | $0 | $-37.3M | $-31.4M |
| 2022 | $1.0M | $-41.3M | $-23.8M |
| 2021 | $7.6M | $-20.7M | $-26.0M |
| 2020 | $1.9M | $-16.8M | $-10.4M |
| 2019 | $0 | – | – |
| 2014 | $9.3M | – | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.04 | -0.05 | -11.1% |
| 2026-03-19 | -0.06 | -0.05 | +21.1% |
| 2025-11-12 | -0.08 | -0.06 | +21.7% |
| 2025-08-12 | -0.08 | -0.07 | +8.7% |
| 2025-05-13 | -0.11 | -0.07 | +34.4% |
| 2025-03-20 | -0.11 | -0.08 | +25.0% |
| 2024-11-13 | -0.13 | -0.10 | +21.1% |
| 2024-08-13 | -0.17 | -0.13 | +25.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
PT $10
PT $7
PT $3
PT $3
PT $8
PT $6
Stats refreshed 2026-10-21 12:15:24 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026